The U.S. Food and Drug Administration (FDA) on Tuesday approved a new Alzheimer’s treatment called donanemab, which could slow progression of the mental disease that impacts millions of Americans, drugmaker Eli Lilly said.
The drug, which will be sold under the name Kisunla, is a type of monoclonal antibody infusion that is administered every four weeks and was shown in trials to slow the pace of decline in the early stages of Alzheimer’s. However, the drug presented several significant safety risks, including brain bleeding and swelling, according to a trial released last year.
